196 related articles for article (PubMed ID: 15086465)
1. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
[TBL] [Abstract][Full Text] [Related]
2. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
Shihab FS; Yi H; Bennett WM; Andoh TF
Kidney Int; 2000 Sep; 58(3):1174-85. PubMed ID: 10972680
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Transplantation; 2004 Mar; 77(5):683-6. PubMed ID: 15021829
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Andoh TF
Am J Transplant; 2002 Feb; 2(2):111-9. PubMed ID: 12099512
[TBL] [Abstract][Full Text] [Related]
5. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Andoh TF
Am J Nephrol; 2006; 26(4):400-7. PubMed ID: 16926534
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
Islam M; Burke JF; McGowan TA; Zhu Y; Dunn SR; McCue P; Kanalas J; Sharma K
Kidney Int; 2001 Feb; 59(2):498-506. PubMed ID: 11168932
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Am J Transplant; 2003 Dec; 3(12):1550-9. PubMed ID: 14629285
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.
Martin-Martin N; Slattery C; McMorrow T; Ryan MP
Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1281-92. PubMed ID: 21880834
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
Shihab FS; Bennett WM; Tanner AM; Andoh TF
Kidney Int; 1997 Sep; 52(3):660-73. PubMed ID: 9291185
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of tea polyphenols on transforming growth factor-beta1 expression in rat with cyclosporine A-induced chronic nephrotoxicity.
Shi SH; Zheng SS; Jia CK; Zhu YF; Xie HY
Acta Pharmacol Sin; 2004 Jan; 25(1):98-103. PubMed ID: 14704129
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Sun QL; Li M; Rui HL; Chen YP
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
[TBL] [Abstract][Full Text] [Related]
14. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.
Bai S; Brunner LJ; Stepkowski SM; Napoli KL; Kahan BD
Transplantation; 2001 Jun; 71(11):1585-92. PubMed ID: 11435969
[TBL] [Abstract][Full Text] [Related]
15. Sodium depletion enhances fibrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy.
Shihab FS; Andoh TF; Tanner AM; Bennett WM
Am J Kidney Dis; 1997 Jul; 30(1):71-81. PubMed ID: 9214404
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
17. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.
Nielsen FT; Ottosen P; Starklint H; Dieperink H
Nephrol Dial Transplant; 2003 Mar; 18(3):491-6. PubMed ID: 12584269
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Feria I; Pichardo I; Juárez P; Ramírez V; González MA; Uribe N; García-Torres R; López-Casillas F; Gamba G; Bobadilla NA
Kidney Int; 2003 Jan; 63(1):43-52. PubMed ID: 12472767
[TBL] [Abstract][Full Text] [Related]
20. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor β/Smad pathways.
Tao Y; Hu L; Li S; Liu Q; Wu X; Li D; Fu P; Wei D; Luo Z
Transplant Proc; 2011 Jun; 43(5):1985-8. PubMed ID: 21693312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
